Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes

By A. Rawshani, A. Rawshani, S. Franzén, B. Eliasson, A. Svensson, Mervete Miftaraj, Darren K Mcguire, N. Sattar, A. Rosengren, S. Gudbjörnsdottir. New England Journal of Medicine, 2017

1,134 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics

View Paper: https://www.semanticscholar.org/paper/9597f3a07ab511fac733d603db92b2740b3b2110

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Marja-Riitta Taskinen
2. G. Bakris
3. I. Graham
4. F. Cosentino
5. Alberico L. Catapano
6. Rhian M. Touyz

In Genetics

1. Marja-Riitta Taskinen
2. E. Michos
3. B. Ference

Citations in the corpus

• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. (2019, background): “The good news is that fatal CVD outcomes have declined significantly in both T1DM and T2DM between 1998 and 2014.(400) DM itself is an independent risk factor for CVD and is associated with a higher risk of CVD, even more so in women.”
• Pathophysiology of diabetes: An overview (2020, background): “Cardiovascular, gastrointestinal, and genitourinary (including sexual) dysfunctions are characteristic manifestations of autonomic neuropathy, whereas foot infections including ulcers requiring amputations and Charcot joint (osteoarthropathy) are often associated with long-term peripheral neuropathy”
• Trends in insulin resistance: insights into mechanisms and therapeutic strategy (2022, background): “Moreover, long-term follow up data from patients with type 1 and type 2 diabetes have confirmed that hyperglycemia is a risk factor for CVD.(357) IR in adipose tissue leads to high FFAs levels,(358) visceral fat accumulation that is associated with elevated levels of plasminogen activator inhibitor ”
• Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes (2020, methodology): “16 Secondary analyses were performed to assess heterogeneity of associations with outcomes of interest according to prespecified baseline characteristics including (1) ASCVD or multiple ASCVD risk factors; (2) history of heart failure; (3) estimated glomerular filtration rate (eGFR); (4) glycated he”
• Diabetes and Hypertension: A Position Statement by the American Diabetes Association (2017, background): “There is evidence that ASCVDmorbidity andmortality have decreased for people with diabetes since 1990 (10,11) likely due in large part to improvements in blood pressure control (12–14).”